PMID- 24667073
OWN - NLM
STAT- MEDLINE
DCOM- 20141217
LR  - 20160526
IS  - 1573-2509 (Electronic)
IS  - 0920-9964 (Linking)
VI  - 155
IP  - 1-3
DP  - 2014 May
TI  - A prospective comparative study of risperidone long-acting injectable for 
      treatment-resistant schizophrenia with dopamine supersensitivity psychosis.
PG  - 52-8
LID - S0920-9964(14)00106-6 [pii]
LID - 10.1016/j.schres.2014.02.022 [doi]
AB  - OBJECTIVE: Dopamine supersensitivity psychosis (DSP) is considered to be one 
      cause of treatment-resistant schizophrenia (TRS). The authors investigated the 
      efficacy of risperidone long-acting injections (RLAI) in patients with TRS and 
      DSP. METHOD: This is a multicenter, prospective, 12-month follow-up, 
      observational study that included unstable and severe TRS patients with and 
      without DSP. 115 patients with TRS were recruited and divided into two groups 
      according to the presence or absence of DSP which was judged on the basis of the 
      clinical courses and neurological examinations. RLAI was administered 
      adjunctively once every 2weeks along with oral antipsychotics. We observed 
      changes in scores for the Brief Psychiatric Rating Scales (BPRS), Clinical Global 
      Impression-Severity of Illness (CGI-S), Global Assessment of Functioning Scale 
      (GAF), and Extrapyramidal Symptom Rating Scale (ESRS) during the study. Of the 
      assessed 94 patients, 61 and 33 were categorized into the DSP and NonDSP groups, 
      respectively. RESULTS: While baseline BPRS total scores, CGI-S scores and GAF 
      scores did not differ, the ESRS score was significantly higher in the DSP group 
      compared with the NonDSP group. Treatment significantly reduced BPRS total scores 
      and CGI-S scores, and increased GAF scores in both groups, but the magnitudes of 
      change were significantly greater in the DSP group relative to the NonDSP group. 
      ESRS scores were also reduced in the DSP group. Responder rates (>/=20% reduction 
      in BPRS total score) were 62.3% in the DSP group and 21.2% in the NonDSP group. 
      CONCLUSIONS: It is suggested that DSP contributes to the etiology of TRS. 
      Atypical antipsychotic drugs in long-acting forms, such as RLAI, can provide 
      beneficial effects for patients with DSP. CLINICAL TRIALS REGISTRATION: UMIN 
      (UMIN000008487).
CI  - Copyright (c) 2014 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Kimura, Hiroshi
AU  - Kimura H
AD  - Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1 
      Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan.
FAU - Kanahara, Nobuhisa
AU  - Kanahara N
AD  - Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1 
      Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan; Division of Medical 
      Treatment and Rehabilitation, Center for Forensic Mental Health, Chiba 
      University, 1-8-1 Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan. Electronic 
      address: kanahara@faculty.chiba-u.jp.
FAU - Komatsu, Naoya
AU  - Komatsu N
AD  - Department of Psychiatry, Dowa-kai Chiba Hospital, 2-508 Hasama-cho, 
      Funabashi-shi, Chiba 274-0822, Japan.
FAU - Ishige, Minoru
AU  - Ishige M
AD  - Department of Psychiatry, Satsuki-kai Sodegaura-satsukidai Hospital, 5-21 
      Nagaura-ekimae, Sodegaura-shi, Chiba 299-0246, Japan.
FAU - Muneoka, Katsumasa
AU  - Muneoka K
AD  - Department of Psychiatry, Gakuji-kai Kimura Hospital, 6-19 Higashihon-machi, 
      Chuou-ku, Chiba-shi, Chiba 260-0004, Japan.
FAU - Yoshimura, Masayuki
AU  - Yoshimura M
AD  - Department of Psychiatry, Doujin-kai Kisaradzu Hospital, 2-3-1 Iwane, 
      Kisaradzu-shi, Chiba 292-0061, Japan.
FAU - Yamanaka, Hiroshi
AU  - Yamanaka H
AD  - Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1 
      Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan; Department of Psychiatry, 
      Chiba Psychiatric Medical Center, 5 Toyosuna, Mihama-ku, Chiba-shi, Chiba 
      261-0024, Japan.
FAU - Suzuki, Tomotaka
AU  - Suzuki T
AD  - Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1 
      Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan; Department of Psychiatry, 
      Koutoku-kai Sato Hospital, 948-1 Kunugizuka, Nanyo-shi, Yamagata 999-2221, Japan.
FAU - Komatsu, Hideki
AU  - Komatsu H
AD  - Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1 
      Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan; Department of Psychiatry, 
      Choshi-Kokoro Clinic, 1-48-8 Shinsei-cho, Choshi-shi, Chiba 288-0056, Japan.
FAU - Sasaki, Tsuyoshi
AU  - Sasaki T
AD  - Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1 
      Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan.
FAU - Hashimoto, Tasuku
AU  - Hashimoto T
AD  - Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1 
      Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan.
FAU - Hasegawa, Tadashi
AU  - Hasegawa T
AD  - Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1 
      Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan.
FAU - Shiina, Akihiro
AU  - Shiina A
AD  - Department of Psychiatry, Chiba University Hospital, 1-8-1 Inohana, Chuou-ku, 
      Chiba-shi, Chiba 260-8670, Japan.
FAU - Ishikawa, Masatomo
AU  - Ishikawa M
AD  - Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1 
      Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan.
FAU - Sekine, Yoshimoto
AU  - Sekine Y
AD  - Division of Medical Treatment and Rehabilitation, Center for Forensic Mental 
      Health, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, 
      Japan; Department of Psychiatry, Choshi-Kokoro Clinic, 1-48-8 Shinsei-cho, 
      Choshi-shi, Chiba 288-0056, Japan.
FAU - Shiraishi, Tetsuya
AU  - Shiraishi T
AD  - Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1 
      Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan.
FAU - Watanabe, Hiroyuki
AU  - Watanabe H
AD  - Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1 
      Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan; Department of Psychiatry, 
      Asahi Hosipital, I-1326, Asahi-shi, Chiba 289-2511, Japan.
FAU - Shimizu, Eiji
AU  - Shimizu E
AD  - Department of Cognitive Behavioral Physiology, Graduate School of Medicine, Chiba 
      University, 1-8-1 Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan.
FAU - Hashimoto, Kenji
AU  - Hashimoto K
AD  - Division of Clinical Neuroscience, Center for Forensic Mental Health, Chiba 
      University, 1-8-1 Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan.
FAU - Iyo, Masaomi
AU  - Iyo M
AD  - Department of Psychiatry, Graduate School of Medicine, Chiba University, 1-8-1 
      Inohana, Chuou-ku, Chiba-shi, Chiba 260-8670, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140323
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
RN  - 0 (Antipsychotic Agents)
RN  - L6UH7ZF8HC (Risperidone)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
CIN - Schizophr Res. 2015 Dec;169(1-3):506. PMID: 26560037
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antipsychotic Agents/*administration & dosage
MH  - Dopamine/adverse effects
MH  - Drug Administration Routes
MH  - Drug Delivery Systems
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Psychiatric Status Rating Scales
MH  - Psychotic Disorders/*complications/drug therapy
MH  - Risperidone/*administration & dosage
MH  - Schizophrenia/*complications/*drug therapy
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Antipsychotics
OT  - Dopamine D2 receptor
OT  - Occupancy rate
OT  - Tolerance
EDAT- 2014/03/29 06:00
MHDA- 2014/12/18 06:00
CRDT- 2014/03/27 06:00
PHST- 2013/09/24 00:00 [received]
PHST- 2014/01/30 00:00 [revised]
PHST- 2014/02/23 00:00 [accepted]
PHST- 2014/03/27 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2014/12/18 06:00 [medline]
AID - S0920-9964(14)00106-6 [pii]
AID - 10.1016/j.schres.2014.02.022 [doi]
PST - ppublish
SO  - Schizophr Res. 2014 May;155(1-3):52-8. doi: 10.1016/j.schres.2014.02.022. Epub 
      2014 Mar 23.